EUCTR2020-001976-14-DK进行中（未招募）1 期
An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 490
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Has histologically confirmed unresectable adenocarcinoma of the colon or rectum
- •- RAS status must have been previously determined (mutant or wild-type) based on local assessment of tumour biopsy
- •- Has received a maximum of 2 prior chemotherapy regimens for the treatment of advanced colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen
- •- Has measurable or non-measurable disease as defined by RECIST version 1.1
- •- Is able to swallow oral tablets
- •- Estimated life expectancy =12 weeks
- •- Has an Eastern Cooperative Oncology Group (ECOG) performance status =1. ECOG should remain=1 during all the screening period
- •- Has adequate organ function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 220
排除标准
- •- Has symptomatic central nervous system metastases that are neurologically unstable or requiring increasing doses of steroids to control CNS disease
- •- Has had certain other recent treatment e.g. major surgery, field radiation, received investigational agent, within the specified time frames prior to randomisation.
- •- Has hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- •- Has certain serious illness or serious medical condition(s) described in
- •the protocol.
- •- Is inappropriate for entry into this study in the judgment of the Investigator.
研究者
相似试验
进行中（未招募）
1 期
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)Refractory metastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001976-14-DEInstitut de Recherches Internationales Servier492
进行中（未招募）
1 期
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)Refractory metastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001976-14-HUInstitut de Recherches Internationales Servier492
进行中（未招募）
1 期
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)EUCTR2020-001976-14-ATInstitut de Recherches Internationales Servier492
进行中（未招募）
1 期
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)Refractory metastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001976-14-BEInstitut de Recherches Internationales Servier492
进行中（未招募）
1 期
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)EUCTR2020-001976-14-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER490